Delivery Order SPE2DB24D8003-SPE2DB25FJUAR
Award Date
3/21/25
Potential Completion Date
3/24/25
Potential Value
$2.7K
Federal Agency
Defense Logistics Agency
Awardee
Dakota Drug, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the procurement of DUPIXENT 300 MG/2 ML PEN 2ML medical supplies. The contract, valued at $13,423.69, has an ultimate completion date of March 7, 2025. Dakota Drug, Inc. is a key supplier for the DLA Troop Support Medical division, providing a wide range of pharmaceutical products, medical supplies, and healthcare equipment to support U.S....
The Defense Logistics Agency (DLA) awarded a $5,601.75 firm fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the provision of DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products. This contract, which does not have a set-aside designation, is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) that Dakota Drug, Inc. holds with the DLA Troop Support Medical's ECAT Generation V Program, which procures commercial medical...
This is a federal contract award by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $4,722.06 Firm Fixed Price Delivery Order contract is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products. The contract has an ultimate completion date of February 5, 2025. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, which allows the company to provide a...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $10,105.17, is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The ultimate completion date for this contract is June 28, 2024. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, valued at...
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $4,194.83 to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of Dupixent 300 mg/2 ml pens. This contract falls under Dakota Drug's larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT Generation V Program, which procures medical equipment, accessories, consumables, and simulation equipment. The contract has an ultimate...
The Defense Logistics Agency (DLA) awarded a $8,232.42 firm fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the provision of DUPIXENT 300 MG/2 ML SYRINGE 2ML. This order was placed under Dakota Drug's $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA, which supports the agency's ECAT Generation V Program for procuring commercial medical equipment, accessories, consumables, and simulation equipment. The contract has an...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business located in Anoka, Minnesota. The $2,294.87 contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, and has an ultimate completion date of June 11, 2025. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, as part of the DLA Troop Support Medical's ECAT Generation...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical division to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, with a ceiling value of $7,211.74, is for the delivery of the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML. The contract has an ultimate completion date of June 6, 2024. Dakota Drug, Inc. is a key supplier for the DLA, holding a significant single-award Indefinite Delivery Contract...
This is a firm fixed-price delivery order contract awarded to Dakota Drug, Inc., a self-certified small disadvantaged business, by the Defense Logistics Agency (DLA) Medical Supply Chain division. The contract, valued at $6,278.19, is for the delivery of 200 mg/1.14 ml DUPIXENT pens to support U.S. Armed Forces medical operations. The contract has a period of performance through November 3, 2023 and is not a set-aside award. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC)...
This federal contract award, valued at $11,442.51, was issued by the Defense Logistics Agency (DLA) Troop Support Medical division to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of DUPIXENT 300 MG/2 ML SYRINGE 2ML, a pharmaceutical product, with a performance period extending through June 12, 2024. Dakota Drug, Inc. is a key supplier of pharmaceutical products, medical supplies, and healthcare equipment to the U.S. Department of Defense. The...